Venture Certified
| 기술평가대출기업(중진공) | 2020-04-24 ~ 2022-04-23 | 20200400849 | 2020-04-24 |
| 연구개발유형 | 2022-06-22 ~ 2025-06-21 | 20220622020027 | 2020-04-24 |
| 연구개발유형 | 2025-06-22 ~ 2028-06-21 | 20250723020006 | 2020-04-24 |
Revenue CAGR +44.5%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 68.5B | 37.9B | 32.8B |
| Operating Profit | 10.4B | 2.7B | 6.9B |
| Net Profit | 10.0B | 2.5B | 6.9B |
| Total Assets | 62.9B | 36.8B | 36.6B |
| Total Liabilities | 23.4B | 6.9B | 9.1B |
| Total Equity | 39.6B | 29.9B | 27.5B |
Debt Ratio Surge (+36pp YoY)
▲ 93.7%
▲ 117.0%
▲ 8.0%
▲ 110.3%
▲ 52.2%
| Name | Position | Role |
|---|---|---|
| 유지석 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "경기 용인시",
"ceo_name": "유지석",
"certificate": [
{
"cert_number": "20200400849",
"changes": "",
"disclosure_date": "2020-04-24",
"first_cert_date": "2020-04-24",
"no": "1",
"type": "기술평가대출기업(중진공)",
"valid_period": "2020-04-24 ~ 2022-04-23"
},
{
"cert_number": "20220622020027",
"changes": "",
"disclosure_date": "2022-06-22",
"first_cert_date": "2020-04-24",
"no": "2",
"type": "연구개발유형",
"valid_period": "2022-06-22 ~ 2025-06-21"
},
{
"cert_number": "20250723020006",
"changes": "",
"disclosure_date": "2025-07-23",
"first_cert_date": "2020-04-24",
"no": "3",
"type": "연구개발유형",
"valid_period": "2025-06-22 ~ 2028-06-21"
}
],
"company_name": "주식회사 렉스팜텍",
"corp_no": "134511-*******",
"financials": {
"2022": {
"capital_stock": 250000000,
"cost_of_sales": 0,
"current_assets": 2606523000,
"current_liabilities": 453752000,
"gross_profit": 3279500000,
"net_income": 686745000,
"net_income_bs": 676124000,
"non_current_assets": 1053858000,
"non_current_liabilities": 457760000,
"non_operating_expenses": 7500000,
"non_operating_income": 536000,
"operating_profit": 693709000,
"revenue": 3279500000,
"sga_expenses": 2585791000,
"total_assets": 3660381000,
"total_equity": 2748869000,
"total_liabilities": 911512000
},
"2023": {
"capital_stock": 250000000,
"cost_of_sales": 0,
"current_assets": 2525249000,
"current_liabilities": 246137000,
"gross_profit": 3789006000,
"net_income": 247352000,
"net_income_bs": 244064000,
"non_current_assets": 1155021000,
"non_current_liabilities": 441200000,
"non_operating_expenses": 28388000,
"non_operating_income": 8784000,
"operating_profit": 266956000,
"revenue": 3789006000,
"sga_expenses": 3522050000,
"total_assets": 3680270000,
"total_equity": 2992933000,
"total_liabilities": 687337000
},
"2024": {
"capital_stock": 250000000,
"cost_of_sales": 0,
"current_assets": 5354432000,
"current_liabilities": 1811033000,
"gross_profit": 6845150000,
"net_income": 1000768000,
"net_income_bs": 963740000,
"non_current_assets": 937414000,
"non_current_liabilities": 524140000,
"non_operating_expenses": 45419000,
"non_operating_income": 3973000,
"operating_profit": 1042214000,
"revenue": 6845150000,
"sga_expenses": 5802936000,
"total_assets": 6291846000,
"total_equity": 3956673000,
"total_liabilities": 2335173000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [],
"main_products": "제제연구/분석연구/신약연구",
"phone": "031-214-****",
"years": [
2024,
2023,
2022
]
}